According to Grok the ATLAS trial will be providing preliminary reports on your husband's scenario "Does adjuvant Apalutimide improve stuff with G8 prostate cancer where primary treatment is RT" (my summary 🙂) in June 2026.
Might be worth keeping an eye out for the results to inform your decision.
For regular HT the "benefits" Are now quite well defined:
"Large older trials (e.g., RTOG, EORTC) showed that long-term ADT improves 10-year overall survival by roughly 8–15 percentage points compared with radiotherapy alone or short-term ADT ". Thanks Grok.